Invex Therapeutics Advances Neurological Research

Invex Therapeutics Ltd. (AU:IXC) has released an update.

Invex Therapeutics Ltd has announced a collaboration with Tessara Therapeutics to research the neuroprotective effects of Exenatide, a drug potentially effective against Alzheimer’s Disease and other neurodegenerative conditions, with initial results expected in Q2 FY25. The company has also successfully completed the IIH EVOLVE Phase III clinical trial, with no further queries from clinical sites or regulators. Financially, Invex maintains a healthy cash reserve of $5.9 million after a quarter with modest R&D expenditures and controlled corporate costs.

For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.